icon-folder.gif   Conference Reports for NATAP  
 
  Infectious Disease Societyof America (IDSA)
IDSA 49th Annual Meeting
October 20-23, 2011
Boston, MA
Back grey_arrow_rt.gif
 
 
 
Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-na´ve Patients: 192 Week Results from STARTMRK
 
 
  Reported by Jules Levin
IDSA 49th Annual Meeting
October 20-23, 2011Boston, MA
 
E. DeJesus1, J. Rockstroh2, J. Lennox3, M. Saag4, A. Lazzarin5, H. Wan6, A. RODGERS6, K. STROHMAIER6, H. TEPPLER6, B-Y. NGUYEN6, R. LEAVITT6, P. SKLAR and the STARTMRK Study Team
1Orlando Immunology Center, Orlando, FL; 2University of Bonn, Bonn, Germany; 3Emory University School of Medicine, Atlanta, GA; 4University of Alabama at Birmingham, Birmingham, AL; 5Universita Vita-Salute San Raffaele, Milan, Italy; 6Merck, Whitehouse Station, NJ

IDSA1.gif

IDSA2.gif

IDSA3.gif

IDSA4.gif

IDSA5.gif

IDSA6.gif

IDSA7.gif

IDSA8.gif

IDSA9.gif

IDSA10.gif